Updates
Thyrocare Technologies Ltd has informed BSE that Mr. Arindam Bhattacharjee, Partner & Portfolio Manager, Mr. Paul Ballantyne, Partner & Portfolio Manager, and Mr. Sebastian Peters, Portfolio Manager, of Genesis Investment Management Ltd., U.K., would be meeting the Company's Chairman & Managing Director, Dr. A. Velumani, at the Company's office at Turbhe, Navi Mumbai by 9.00 A.M. on December 13, 2016. The meeting is being organized by Motilal Oswal Securities Ltd.... Updates
Thyrocare Technologies Ltd has informed BSE that the Company's Chairman & Managing Director, Dr. A. Velumani, would be meeting Mr. Sunil Asnani, Portfolio Manager, Matthews Asia, belonging to Matthew International Capital Management LLC, at our office at Turbhe, Navi Mumbai by 9.30 A.M. on December 08, 2016. The meeting is being organized by Nomura group.... Updates
Thyrocare Technologies Ltd has informed BSE that the Chairman & Managing Director, Dr. A. Velumani, would be meeting Mr. Krishna Kumar, Portfolio Manager, Eastsprings Investments (Singapore) Limited, a wholly owned subsidiary of Prudential Plc of UK, over breakfast at Hotel Trident, BKC, Mumbai, by 8.00 A.M. on December 07, 2016. The meeting is being organized by Credit Suisse Securities (India) Private Limited, Mumbai.... 2 long-term picks to invest in: Moneylicious
Thyrocare Technologies and LIC Housing Finance are two stocks that can be held on to for 12-15 months'' Updates
Thyrocare Technologies Ltd has informed BSE that the Company's Chairman & Managing Director, Dr. A. Velumani, has been invited by IDFC Securities Limited to attend IDFC Annual Investor Conference- The Stock called India 2016 on November 16, 2016 at The Taj Lands End at Mumbai. The conference is scheduled to start from 09.00 a.m and end at 05.00 p.m.... Thyrocare plans to set up more laboratories
Diagnostic and pre-care laboratory chain Thyrocare Technologies will expand to 25 laboratories from the current seven by 2020. The company will invest 50 crore annually to fund the expansion... Thyrocare to invest Rs 250 cr, eyes Rs 1,000 cr revenue by 2020
Firm will expand lab centres to 25, from seven currently, and increase franchisees from 1,200 to 5,000 Standalone & Consolidated Financial Results, Limited Review Report for September 30, 2016
Thyrocare Technologies Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Consolidated Financial Results for the period ended September 30, 20163. Standalone Limited Review for the period ended September 30, 20164. Consolidated Limited Review for the period ended September 30, 2016 Details of Earnings Call
Thyrocare Technologies Ltd has informed BSE about Earnings Call to discuss the Q2 FY 17 results.